1
|
Mamelak AN and Jacoby DB: Targeted
delivery of antitumoral therapy to glioma and other malignancies
with synthetic chlorotoxin (TM-601). Expert Opin Drug Deliv.
4:175–186. 2007. View Article : Google Scholar : PubMed/NCBI
|
2
|
Goodenberger ML and Jenkins RB: Genetics
of adult glioma. Cancer Genet. 205:613–621. 2012. View Article : Google Scholar : PubMed/NCBI
|
3
|
Smoll NR, Gautschi OP, Schatlo B, Schaller
K and Weber DC: Relative survival of patients with supratentorial
low-grade gliomas. Neuro Oncol. 14:1062–1069. 2012. View Article : Google Scholar : PubMed/NCBI
|
4
|
Olson JD, Riedel E and DeAngelis LM:
Long-term outcome of low-grade oligodendroglioma and mixed glioma.
Neurology. 54:1442–1448. 2000. View Article : Google Scholar : PubMed/NCBI
|
5
|
Ohgaki H and Kleihues P: Population-based
studies on incidence survival rates and genetic alterations in
astrocytic and oligodendroglial glioma. J Neuropathol Exp Neurol.
64:479–489. 2005.PubMed/NCBI
|
6
|
Plaks V, Kong N and Werb Z: The cancer
stem cells niche, How essential is the niche in regulating stemness
of tumor cells? Cell Stem Cell. 16:225–238. 2015. View Article : Google Scholar : PubMed/NCBI
|
7
|
Wang L, Xue Y, Shen Y, Li W, Cheng Y, Yan
X, Shi W, Wang J, Gong Z, Yang G, et al: Claudin 6: A novel surface
marker for characterizing mouse pluripotent stem cells. Cell Res.
22:1082–1085. 2012. View Article : Google Scholar : PubMed/NCBI
|
8
|
Gilbertson RJ and Rich JN: Making a
tumour's bed: Glioblastoma stem cells and the vascular niche. Nat
Rev Cancer. 7:733–736. 2007. View
Article : Google Scholar : PubMed/NCBI
|
9
|
Chen L, Chen XR, Chen FF, Liu Y, Li P,
Zhang R, Yan K, Yi YJ, Xu ZM and Jiang XD: MicroRNA-107 inhibits
U87 glioma stem cells growth and invasion. Cell Mol Neurobiol.
33:651–657. 2013. View Article : Google Scholar : PubMed/NCBI
|
10
|
Galli R, Binda E, Orfanelli U, Cipelletti
B, Gritti A, De Vitis S, Fiocco R, Foroni C, Dimeco F and Vescovi
A: Isolation and characterization of tumorigenic, stem-like neural
precursors from human glioblastoma. Cancer Res. 64:7011–7021. 2004.
View Article : Google Scholar : PubMed/NCBI
|
11
|
Gaedicke S, Braun F, Prasad S, Machein M,
Firat E, Hettich M, Gudihal R, Zhu X, Klingner K, Schüler J, et al:
Noninvasive positron emission tomography and fluorescence imaging
of CD133+ tumor stem cells. Proc Natl Acad Sci USA. 111:E692–E701.
2014. View Article : Google Scholar : PubMed/NCBI
|
12
|
Lubanska D, Market-Velker BA, deCarvalho
AC and Mikkelsen T: Fidalgo daS ilva E and Porter LA: The
cyclin-like protein Spy1 regualtes growth and division
characteristics of the CD133+ population in human
glioma. Cancer Cell. 25:64–76. 2014. View Article : Google Scholar : PubMed/NCBI
|
13
|
Jin X, Jin X, Jung JE, Beck S and Kim H:
Cell surface nestin is a biomarker for glioma stem cells. Biochem
Biophys Res Commun. 433:496–501. 2013. View Article : Google Scholar : PubMed/NCBI
|
14
|
Dell'Albani P: Stem cell markers in
gliomas. Neurochem Res. 33:2407–2415. 2008. View Article : Google Scholar : PubMed/NCBI
|
15
|
Strojnik T, Røsland GV, Sakariassen PO,
Kavalar R and Lah T: Neural stem cell markers, nestin and musashi
proteins, in the progrssion of human glioma, Correlation of nestin
with prognosis of patient survival. Surg Neurol. 68:133–143. 2007.
View Article : Google Scholar : PubMed/NCBI
|
16
|
Raso A, Negri F, Gregorio A, Nozza P,
Mascelli S, De Marco P, Merello E, Milanaccio C, Ravegnani M, Cama
A, et al: Successful isolation and long-term establishment of a
cell line with stem cell-like features from an anaplastic
medulloblastoma. Neuropathol Appl Neurobiol. 34:306–315. 2008.
View Article : Google Scholar : PubMed/NCBI
|
17
|
Hemmati HD, Nakano I, Lazareff JA,
Masterman-Smith M, Geschwind DH, Bronner-Fraser M and Kornblum HI:
Cancerous stem cells can arise from pediatric brain tumors. Proc
Natl Acad Sci USA. 100:15178–15183. 2003. View Article : Google Scholar : PubMed/NCBI
|
18
|
Ignatova TN, Kukekov VG, Laywell ED,
Suslov ON, Vrionis FD and Steindler DA: Human cortical glial tumors
contain neural stem-like cells expressing astroglial and neuronal
markers in vitro. Glia. 39:193–206. 2002. View Article : Google Scholar : PubMed/NCBI
|
19
|
Dolgova EV, Alyamkina EA, Efremov YR,
Nikolin VP, Popova NA, Tyrinova TV, Kozel AV, Minkevich AM,
Andrushkevich OM, Zavyalov EL, et al: Identification of cancer stem
cells and a strategy for their elimination. Cancer Biol Ther.
15:1378–1394. 2014. View Article : Google Scholar : PubMed/NCBI
|
20
|
Beier D, Hau P, Proescholdt M, Lohmeier A,
Wischhusen J, Oefner PJ, Aigner L, Brawanski A, Bogdahn U and Beier
CP: CD133(+) and CD133(−) glioblastoma-derived cancer stem cells
show differential growth characteristics and molecular profiles.
Cancer Res. 67:4010–4015. 2007. View Article : Google Scholar : PubMed/NCBI
|
21
|
Bao S, Wu Q, McLendon RE, Hao Y, Shi Q,
Hjelmeland AB, Dewhirst MW, Bigner DD and Rich JN: Glioma stem
cells promote radioresistance by preferential activation of the DNA
damage response. Nature. 444:756–760. 2006. View Article : Google Scholar : PubMed/NCBI
|
22
|
Ma C, Li Y, Zhang X, Zhao G and Xu H:
Levels of vascular endothelial growth factor and matrix
metalloproteinase-9 proteins in patients with glioma. J Int Med
Res. 42:198–204. 2014. View Article : Google Scholar : PubMed/NCBI
|
23
|
Li Q, Qiao G, Ma J and Li Y:
Downregulation of VEGF expression attenuates maligant biological
behavior of C6 glioma stem cells. Int J Oncol. 44:1581–1588.
2014.PubMed/NCBI
|
24
|
Plate KH, Breier G, Millauer B, Ullrich A
and Risau W: Up-regulation of vascular endothelial growth factor
and its cognate receptors in a rat glioma model of tumor
angiogenesis. Cancer Res. 53:5822–5827. 1993.PubMed/NCBI
|
25
|
Das S and Marsden PA: Angiogenesis in
glioblastoma. N Engl J Med. 369:1561–1563. 2013. View Article : Google Scholar : PubMed/NCBI
|
26
|
Whitman M, Downes CP, Keeler M, Keller T
and Cantley L: Type I phosphatidylinositol kinase makes a novel
inositol phospholipid, phosphatidylinositol-3-phosphate. Nature.
332:644–646. 1988. View
Article : Google Scholar : PubMed/NCBI
|
27
|
Vara Fresno JA, Casado E, de Castro J,
Cejas P, Belda-Iniesta C and González-Barón M: PI3K/Akt signaling
pathway and cancer. Cancer Treat Rev. 30:193–204. 2004. View Article : Google Scholar : PubMed/NCBI
|
28
|
Shin BC, Suzuki M, Inukai K, Anai M, Asano
T and Takata K: Multiple isoforms of the regulatory subunit for
phosphatidylinositol 3 kinase (PI3-kinase) are expressed in neurons
in the rat brain. Biochem Biophys Res Commun. 246:313–319. 1998.
View Article : Google Scholar : PubMed/NCBI
|
29
|
Weller M, Weber RG and Willscher E:
Molecular classification of diffuse cerebral WHO grade II/III
gliomas using genome- and transcriptome-wide profiling improves
stratification of prognostically distinct patient groups. Acta
Neuropathol. 129:679–693. 2015. View Article : Google Scholar : PubMed/NCBI
|
30
|
Simonetti G, Gaviani P, Botturi A,
Innocenti A, Lamperti E and Silvani A: Clinical management of grade
III oligodendroglioma. Cancer Manag Res. 7:213–223. 2015.
View Article : Google Scholar : PubMed/NCBI
|
31
|
Zhang C, Bao Z, Zhang W and Jiang T:
Progress on molecular biomarkers and classification of malignant
gliomas. Front Med. 7:150–156. 2013. View Article : Google Scholar : PubMed/NCBI
|
32
|
Kahramancetin N and Tihan T: Aggressive
behavior and anaplasia in pleomorphic xanthoastrocytoma a plea for
a revision of the current WHO classification. CNS Oncol. 2:523–530.
2013. View Article : Google Scholar : PubMed/NCBI
|
33
|
Schafer ML, Maurer MH, Synowitz M,
Wustefeld J, Marnitz T, Streitparth F and Wiener E: Low- (WHO II)
and anaplastic (WHO III) gliomas, Differences in morphology and MRI
signal intensities. Eur Radiol. 23:2846–2853. 2013. View Article : Google Scholar : PubMed/NCBI
|
34
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
35
|
Louis DN, Ohgaki H, Wiestler OD, Cavenee
WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007
WHO classification of tumours of the central nervous system. Acta
Neurophthol. 114:97–109. 2007. View Article : Google Scholar
|
36
|
Ostrom QT, Gittleman H, Farah P, Ondracek
A, Chen Y, Wolinsky Y, Stroup NE, Kruchko C and Barnholtz-Sloan JS:
CBTRUS statistical report Primary brain and central nervous system
tumors diagnosed in the United States in 2006-2010. Neuro Oncol 15
Suppl. 2:ii1–ii56. 2013.
|
37
|
Olar A and Aldape KD: Biomarkers
classification and therapeutic decision-making for malignant
gliomas. Curr Treat Options Oncol. 13:417–436. 2012. View Article : Google Scholar : PubMed/NCBI
|
38
|
Ichimura K: Molecular pathogenesis of IDH
mutations in gliomas. Brain Tumor Pathol. 29:131–139. 2012.
View Article : Google Scholar : PubMed/NCBI
|
39
|
Birner P, Pusch S, Christov C, Mihaylova
S, Toumangelova-Uzeir K, Natchev S, Schoppmann SF, Tchorbanov A,
Streubel B, Tuettenberg J and Guentchev M: Mutant IDH1 inhibits
PI3K/Akt signaling in human glioma. Cancer. 120:2440–2447. 2014.
View Article : Google Scholar : PubMed/NCBI
|
40
|
Olson RA, Brastianos PK and Palma DA:
Prognostic and predictive value of epigenetic silencing of MGMT in
patients with high grade gliomas, A systematic review and
meta-analysis. J Neuroncol. 105:325–335. 2011. View Article : Google Scholar
|
41
|
Hegi ME, Diserens AC, Gorlia T, Hamou MF,
de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani
L, et al: MGMT gene silencing and benefit from temozolomide in
glioblastoma. N Eng J Med. 352:997–1003. 2005. View Article : Google Scholar
|
42
|
Brandes AA, Franceschi E, Tosoni A, Blatt
V, Pession A, Tallini G, Bertorelle R, Bartolini S, Calbucci F,
Andreoli A, et al: MGMT promoter methylation status can predict the
incidence and outcome of pseudoprogression after concomitant
radiochemotherapy in newly diagnosed glioblastoma patients. J Clin
Oncol. 26:2192–2197. 2008. View Article : Google Scholar : PubMed/NCBI
|
43
|
Ohgaki H and Kleihues P: Genetic pathways
to primary and secondary glioblastoma. Am J Pathol. 170:1445–1453.
2007. View Article : Google Scholar : PubMed/NCBI
|
44
|
Bonnet D and Dick JE: Human acute myeloid
leukemia is organized as a hierarchy that originates from a
primitive hematopoietic cell. Nat Med. 3:730–737. 1997. View Article : Google Scholar : PubMed/NCBI
|
45
|
Singh SK, Clarke ID, Terasaki M, Bonn VE,
Hawkins C, Squire J and Dirks PB: Identification of a cancer stem
cell in human brain tumors. Cancer Res. 63:5821–5828.
2003.PubMed/NCBI
|
46
|
Al-Hajj M, Wicha MS, Benito-Hernandez A,
Morrison SJ and Clarke MF: Prospective identification of
tumorigenic breast cancer cells. Proc Natl Acad Sci USA.
100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
|
47
|
O'Brien CA, Pollett A, Gallinger S and
Dick JE: A human colon cancer cell capable of initiating tumor
growth in immunodeficient mice. Nature. 445:106–110. 2007.
View Article : Google Scholar : PubMed/NCBI
|
48
|
Zhang S, Balch C, Chan MW, Lai HC, Matei
D, Schilder JM, Yan PS, Huang TH and Nephew KP: Identification and
characterization of ovarian cancer-initiating cells from primary
human tumors. Cancer Res. 68:4311–4320. 2008. View Article : Google Scholar : PubMed/NCBI
|
49
|
Li C, Heidt DG, Dalerba P, Burant CF,
Zhang L, Adsay V, Wicha M, Clarke MF and Simeone DM: Identification
of pancreatic cancer stem cells. Cancer Res. 67:1030–1037. 2007.
View Article : Google Scholar : PubMed/NCBI
|
50
|
Maitland NJ and Collins AT: Prostate
cancer stem cells: A new target for therapy. J Clin Oncol.
26:2862–2870. 2008. View Article : Google Scholar : PubMed/NCBI
|
51
|
Temple S: Division and differentiation of
isolated CNS blast cells in microculture. Nature. 340:471–473.
1989. View Article : Google Scholar : PubMed/NCBI
|
52
|
Reynolds BA, Tetzlass W and Weiss S: A
Multipotent EGF-responsive striatal embryonic progenitor cell
produces neurons and astrocytes. J Neurosci. 12:4564–4574.
1992.
|
53
|
Reynolds BA and Weiss A: Generation of
neurons and astrocytes from isolated cells of the adult mammalian
central nervous system. Science. 255:1707–1710. 1992. View Article : Google Scholar : PubMed/NCBI
|